Jafron Biomedical Co
Jafron Biomedical Co is a Chinese public medical device company (Shenzhen ChiNext, ticker 300529) that designs, manufactures, and sells proprietary resin-based hemoperfusion cartridges plus blood purification equipment, serving 8,000+ hospitals globally across nephrology, hepatology, critical care, and immunology indications.
- Company typePublic
- Founded2002
- HeadquartersZhuhai, China
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Jafron Biomedical Co does
Jafron Biomedical Co is a Chinese medical device company specializing in blood purification, with a specific focus on resin-based whole-blood hemoperfusion technology. Founded in 2002 via management buyout of the loss-making Lizhu Biomedical Materials Factory and listed on the Shenzhen Stock Exchange ChiNext (stock code 300529), the company pioneered the world's first resin-based whole-blood hemoperfusion system using proprietary neutral macroporous adsorption resin. The company operates from Zhuhai, China, with additional production bases in Beijing/Tianjin and Hubei, a Shenzhen Center opened in January 2026 for international business, and global distribution across 90+ countries and 8,000+ hospitals (6,000+ in China).
The product portfolio centers on the HA-series disposable hemoperfusion cartridges — HA130, KHA130, and pHA130 for nephrology/ESRD; HA330, HA380, and CA330 for critical care and sepsis; HA280 and DNA230 for immunology and autoimmune disease; BS330 and HA330-II for liver failure support under the DPMAS (Double Plasma Molecular Adsorption System) modality. The proprietary neutral macroporous resin chemistry, combined with biocompatible collodion coatings and specialized pore structures, enables adsorption of middle/large molecule toxins and protein-bound toxins directly from whole blood without plasma separation. Capital equipment includes the DX-10 intelligent multi-mode blood purification system (CRRT machine), the JF-800A hemoperfusion machine, and the Future F20 blood purifier. Dialysis products include high/low-flux dialyzers, tubing circuits, and dialysate solutions. The company also operates the Aiduoduo (爱多多) digital health management platform offering kidney-disease patient education tools, nutritional supplements, and kidney-disease insurance — forming an integrated device-consumable-pharmaceutical-insurance-digital stack around the patient.
Jafron's revenue model combines high-margin recurring disposable consumable sales (6 million+ units annually; cartridges are single-use and required per treatment session for chronic dialysis patients, creating volume-driven repeat demand) with capital equipment revenue (DX-10 priced at 148,000 RMB/unit). Distribution is executed through direct enterprise field sales to hospitals via academic-promotion specialists in China and through country-level distributors internationally, supported by a 300,000+ annual interactions customer service center, continuous clinical training, and 3,000+ clinical publications including 300+ SCI papers. The company holds 387 patents (105 invention patents), ISO 13485 GMP certification for 12 consecutive years, CE mark, and the National Manufacturing Single Champion Enterprise designation. Domestic market share is 70%+ in the hemoperfusion segment. Key risk: the recent revenue trajectory shows decline from a 2021 peak, partially recovering into 2025, suggesting exposure to industry-level pricing pressure from China's DRG/DIP reimbursement reform and hemoperfusion-specific centralized procurement dynamics.
Jafron Biomedical Co firmographics
Firmographics- Name
- Jafron Biomedical Co
- Legal name
- 健帆生物科技集团股份有限公司
- Website
- https://jafron.com
- Company type
- Public
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Jafron Biomedical Co is a Chinese public medical device company (Shenzhen ChiNext, ticker 300529) that designs, manufactures, and sells proprietary resin-based hemoperfusion cartridges plus blood purification equipment, serving 8,000+ hospitals globally across nephrology, hepatology, critical care, and immunology indications.
- Ownership category
- akta.pro rank
Jafron Biomedical Co industry classification
Industry- Product category
- Blood Purification Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Renal Replacement Therapy Consumables (Bloodlines, Filters, Cartridges) (HLAHAKAH)
- akta.pro secondary industry
- Transfusion Medicine & Immunohematology (Blood Bank) (HLAFAMAG)
Keywords
Where Jafron Biomedical Co is headquartered
LocationHeadquarters
- HQ city
- Zhuhai
- HQ country
- China
- HQ region
- Asia
Offices7 records
Markets served
Jafron Biomedical Co business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- Disposable Blood Hemoperfusion Devices: High-margin consumable products including HA series hemoperfusion devices for nephrology, hepatology, critical care, and immune diseases. Single-use products requiring repeated purchases from dialysis patients. Revenue generated from 500+ annual clinical uses and 6000+ hospital customers.
- Blood Purification Equipment (DX-10): Capital equipment sales including DX-10 blood purification machines priced at 148,000 yuan per unit. Equipment enables CRRT, artificial liver, and immune adsorption treatments in hospitals. 4000+ units installed across 2000+ hospitals.
- Dialysis Consumables and Accessories: Complete dialysis product line including dialysis tubing, high/low flux dialyzers, dialysate powder/liquid, and JF-800A hemoperfusion machines. Products support combination therapies for comprehensive kidney disease management.
- Chronic Disease Management Services: Health management services, nutritional products, health supplements, kidney disease insurance (爱多多), and intelligent management systems for comprehensive patient care throughout the disease journey.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | One time/ perpetual license | DX-10 Blood Purification Machine - National unified retail price |
| Unit Pricing | Pay-as-you-go | HA130 Hemoperfusion Device - Cost efficiency advantage |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Jafron Biomedical Co product offering
Product offeringCore offering
Jafron Biomedical Co manufactures and sells proprietary blood purification medical devices and consumables, centered on resin-based disposable hemoperfusion cartridges (HA series) and multi-mode blood purification equipment (DX-10). The company also produces dialysis consumables (dialyzers, tubing, dialysate), plasma separation devices, immune adsorbers, and runs a digital patient health management platform for kidney disease patients.
Product overview
Jafron Biomedical Co is a vertically integrated medical device company specializing in blood purification. Its portfolio spans a unified ecosystem of proprietary hemoperfusion consumables, blood purification equipment, dialysis products, and digital health management services. The core product line centers on HA-series disposable hemoperfusion cartridges (HA130, KHA130, pHA130 for kidney disease; HA330, HA380, CA330 for critical care; HA280 for immune diseases; HA330-II for liver support), which use proprietary neutral macroporous adsorption resin to clear toxins. The BS330 plasma bilirubin adsorber and DNA230 immune adsorber extend into liver and autoimmune applications. Equipment includes the DX-10 multi-mode blood purification system (CRRT), JF-800A hemoperfusion machine, and Future F20 blood purifier. Dialysis products include dialyzers (high/low flux), tubing circuits, and dialysate solutions. The company also operates the Aiduoduo (爱多多) digital health management platform offering patient management tools, kidney disease insurance, and nutritional supplements — forming a 'device耗材-药品-保险-慢病管理' full-chain ecosystem around the patient.
Differentiator
Problem solved
Functional benefit
Brands
- 爱多多健康管理: 肾科全病程健康管理服务品牌，提供医护患教数智化管理工具及专业健康管理团队
- DPMAS
Products and services
- HA130 Disposable Blood Hemoperfusion Cartridge (HA130 一次性使用血液灌流器)
Companies that use Jafron Biomedical Co
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Jafron Biomedical Co technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Jafron Biomedical Co partnerships and signals
Strategic signalScale indicators11 records
Recent moves18 records
Expansion highlights6 records
Jafron Biomedical Co competitors and assessment
Company assessmentDirect peers
- Asahi Kasei Medical: Japanese subsidiary of Asahi Kasei Corporation manufacturing dialysis membranes, plasma fractionation, and blood purification devices (e.g., Leucocephron for selective adsorption). Directly comparable as a resin/membrane-based blood purification technology company serving the same nephrology and critical care customers as Jafron.
- Kaneka Corporation: Japanese chemical/medical company with blood purification products including selective plasma exchange (Liposorber for LDL apheresis) and immunoadsorption columns. Comparable as a resin-based selective blood purification technology company targeting autoimmune and lipid disorders — directly competing with Jafron's HA280 and DNA230 immunoadsorption products.
- CytoSorbents Corporation: US-based company developing CytoSorb cytokine adsorption cartridges for sepsis, cytokine storm, and critical care blood purification. Directly comparable as a specialty blood purification company with a single-product technology platform addressing the same sepsis/cytokine storm clinical use case as Jafron's CA330 and HA380.
- Toray Medical: Japanese division of Toray Industries manufacturing cellulose and synthetic dialysis membranes, hemoconcentrators, and CRRT filters. Comparable as a specialty blood purification materials company with proprietary membrane/adsorption technology serving nephrology and critical care — directly overlapping with Jafron's consumable product positioning.
Emerging players
- ExThera Medical: US company developing the Seraph 100 blood filter for pathogen removal in bloodstream infections. Comparable as an emerging single-platform blood purification device company targeting critical care applications that overlap with Jafron's HA-series critical care cartridges.
- Spectral Medical: Canadian company developing the Toraymyxin PMX endotoxin removal cartridge and a sepsis diagnostic. Comparable as an emerging blood purification player targeting sepsis (similar to Jafron's CA330/HA380) with regulatory-stage products competing for similar ICU applications.
Broad incumbents
- Nipro Corporation: Japanese medical device manufacturer with significant dialyzer and dialysis equipment business, including hollow-fiber membranes and dialysate solutions. Comparable as a vertically integrated dialysis consumable supplier targeting the same nephrology market segment as Jafron's dialysis product line.
- Fresenius Medical Care: Global dialysis services and products leader operating 4000+ dialysis centers and manufacturing dialyzers, CRRT machines, and related consumables. Comparable as the dominant incumbent in renal replacement therapy that Jafron's hemoperfusion cartridges complement alongside standard hemodialysis.
- Baxter International: US medical device company with extensive CRRT and dialysis portfolio (e.g., Prismax system, HF440 dialyzer). Comparable through overlapping critical care blood purification products (CA330-style cytokine adsorption equivalents) and global hospital sales channels targeting the same ICU/nephrology customer base.
Others
- B. Braun Avitum: German B. Braun's dialysis and blood purification division manufacturing hemodialysis machines, dialyzers, and CRRT systems for global hospital customers. Comparable as a major European-headquartered incumbent serving the same hospital nephrology and ICU segments.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
Jafron Biomedical Co compliance and trust
Trust signalCompliance3 records
Jafron Biomedical Co financial estimates
Financial estimateRevenue estimate
Valuation estimate
Jafron Biomedical Co leadership team
Management profileNumber of profiles
Profiles6 records
Jafron Biomedical Co subsidiaries and ownership
Company hierarchySubsidiaries5 records
Jafron Biomedical Co funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Jafron Biomedical Co M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Jafron Biomedical Co
What does Jafron Biomedical Co do?
Jafron Biomedical Co manufactures and sells proprietary blood purification medical devices and consumables, centered on resin-based disposable hemoperfusion cartridges (HA series) and multi-mode blood purification equipment (DX-10). The company also produces dialysis consumables (dialyzers, tubing, dialysate), plasma separation devices, immune adsorbers, and runs a digital patient health management platform for kidney disease patients.
Is Jafron Biomedical Co a public or private company?
Jafron Biomedical Co is a public company. It is classified as public and is currently operating.
When was Jafron Biomedical Co founded?
Jafron Biomedical Co was founded in 2002. It employs 1,001 to 5,000 people.
Where is Jafron Biomedical Co based?
Jafron Biomedical Co is headquartered in Zhuhai, China, in the Asia region.
How does Jafron Biomedical Co make money?
Four revenue lines are on record. Disposable Blood Hemoperfusion Devices are the primary driver. The others are blood Purification Equipment (DX-10), dialysis Consumables and Accessories and chronic Disease Management Services.
Who are Jafron Biomedical Co's main competitors?
Direct peers on record are Asahi Kasei Medical, Kaneka Corporation, CytoSorbents Corporation and Toray Medical. Emerging players are ExThera Medical and Spectral Medical. Broad incumbents are Nipro Corporation, Fresenius Medical Care and Baxter International. B. Braun Avitum is listed as an others.
Does Jafron Biomedical Co have an API?
No public API is recorded for Jafron Biomedical Co.
What industry is Jafron Biomedical Co in?
Jafron Biomedical Co's product category is Blood Purification Medical Devices. Its primary akta.pro industry code is HLAHAKAH, Renal Replacement Therapy Consumables (Bloodlines, Filters, Cartridges), with a secondary code of HLAFAMAG, Transfusion Medicine & Immunohematology (Blood Bank). Its NAICS code is 339112 and its SIC code is 3841.